Oculis Holding
OCS
9 hedge funds and large institutions have $40.9M invested in Oculis Holding in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
29% more funds holding
Funds holding: 7 → 9 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.69% less ownership
Funds ownership: 10.95% → 9.26% (-1.7%)
8% less capital invested
Capital invested by funds: $44.3M → $40.9M (-$3.4M)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$179K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$35.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$13.1K |
| 4 |
JP Morgan Chase
New York
|
+$12 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBPIA
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
|
-$3.51M |
| 2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$2.69M |
| 3 |
NFGH
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
-$989K |
| 4 |
SC
Searle & Co
Greenwich,
Connecticut
|
-$11K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PBPIA
1
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
| $19.2M | -$3.51M | -292,870 | -16% |
|
|
2
Aberdeen Group
Edinburgh,
United Kingdom
| $14.8M | -$2.69M | -224,699 | -15% |
|
|
NFGH
3
Nan Fung Group Holdings
Kai Tak,
Hong Kong
| $5.26M | -$989K | -82,555 | -16% |
|
|
CLOS
4
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
| $1.15M | – | – | – |
|
|
5
Bank of America
Charlotte,
North Carolina
| $240K | +$35.6K | +2,968 | +18% |
|
|
6
Geode Capital Management
Boston,
Massachusetts
| $180K | +$179K | +14,944 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| $13.2K | +$13.1K | +1,097 | New |
|
|
DCM
8
Dupont Capital Management
Wilmington,
Delaware
| $48 | – | – | – |
|
|
9
JP Morgan Chase
New York
| $12 | +$12 | +1 | New |
|
|
SC
10
Searle & Co
Greenwich,
Connecticut
| – | -$11K | -10,000 | Closed |
|
OCS Hedge Fund Activity: Q1 2024 in Review
9 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Oculis Holding (OCS) for Q1 2024, worth a combined $40.9M — down 7.7% from $44.3M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new OCS positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $179K. The largest seller was Pivotal bioVenture Partners Investment Advisor, cutting an estimated $3.51M.
- 9 institutional investors held Oculis Holding (OCS) as of Q1 2024, up from 7 in Q4 2023.
- Funds reported $40.9M of Oculis Holding stock for Q1 2024, down 7.7% quarter-over-quarter.
- 3 funds opened new Oculis Holding positions in Q1 2024 and 1 closed out, a net change of +2 holders.
- The largest Oculis Holding buyer in Q1 2024 was Geode Capital Management, an estimated $179K added.
- The largest Oculis Holding seller in Q1 2024 was Pivotal bioVenture Partners Investment Advisor, an estimated $3.51M sold.
Based on aggregated 13F filings for Q1 2024.